Patritumab

Patritumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	HER3
Clinical data
ATC code	none;
Identifiers
CAS Number	1262787-83-6;
ChemSpider	none;
UNII	86780VJI1Q;
KEGG	D12185;
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).;
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).

Patritumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator.^[1]^[2]

Clinical trials

It is to be included in a new arm of the I-SPY 2 breast cancer trial.^[4]

^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
^ Clinical trial number NCT02633800 for "A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and Neck" at ClinicalTrials.gov
^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.